Table 1.
Baseline characteristics of included studies.
| Study ID |
Study design |
Data source | Follow-up |
Sample size (TAVR/SAVR) |
Age (years) |
DM | Hypertension | COPD | CAD | PCI | STS score | Valve for TAVR | AVG (mmHg) | AVA (cm2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Makkar, (2020) (11) | RCT | PARTNER 2 | 5 year | 1011/1021 | 82/82 | 38/34 | / | 31.8/30.0 | 69/67 | 27/28 | 5.8/5.8 | Edwards Lifesciences SAPIEN XT heart-valve system | 45/45 | 0.7/0.7 |
| Reardon, (2017) (12) | RCT | SURTAVIC | 2 year | 864/796 | 80/80 | 34/35 | 93/90 | / | 63/64 | 21/21 | 4.4/4.5 | 84% CoreValve bioprosthesis/16% Evolut R bioprosthesis | / | / |
| Thyregod et al. (2019) (13) | RCT | NOTION | 5 year | 145/135 | 79/79 | 18/21 | 71/76 | 12/12 | / | 8/9 | 2.9/3.1 | Medtronic CoreValve System(TM) | / | / |
| Mack et al. (2019) (14) | RCT | PARTNER 3 | 2 year | 496/454 | 73/74 | 31/30 | / | 5/6 | 28/28 | / | 1.9/1.9 | SAPIEN 3 system | 49/48 | 0.8/0.8 |
| Popma, (2019) (15) | RCT | Evolut Low Risk Trial | 1 year | 725/678 | 74/73 | 31/31 | 85/83 | 15/18 | 14/13 | 1.9/1.9 | 3.6% CoreValve/74.1% Evolut R/22.3% Evolut PRO | 47/47 | 0.8/0.8 | |
| Toff (2020) (16) | RCT | UK TAVI | 1 year | 458/455 | 81/81 | 23/25 | 72/72 | / | 30/32 | 12/9 | 2.6/2.7 | SAPIEN/CoreValve/Evolut/others | / | 0.7/0.7 |
| Nielsen, (2012) (17) | RCT | STACCATO | 1 year | 34/36 | 80/82 | 3/8 | / | 3/3 | / | 3.1/3.4 | Edwards Lifesciences SAPIEN | / | 0.7/0.7 | |
| Gleason, (2018) (18) | RCT | US-CoreValve High Risk Study | 5 year | 390/357 | 83/83 | 35/45 | 95/96 | / | 75/76 | 34/38 | 7.3/7.5 | CoreValve self-expanding prosthesis | / | / |
| Fusari, (2012) (19) | PSM | Italy, 2008–2009 | 1 year | 30/30 | 81/78 | 23/7 | 93/77 | 30/33 | 37/33 | / | 6.6/6.1 | / | 53/52 | 0.7/0.7 |
| Virtanen, (2019) (20) | PSM | FinnValve registry | 3 year | 304/304 | 78/78 | 22/22 | / | 19/19 | 17/16 | 2.1/2.1 | / | / | / | |
| Latib, (2012) (21) | PSM | Italy, 2003–2008 | 1 year | 111/111 | 81/80 | 19/22 | 70/69 | 26/23 | 40/46 | / | 4.6/4.6 | 58.3% EdwardsSAPIEN, Edwards-SAPIEN XT/ 41.7% CoreValve | ||
| Tamburino, (2015) (22) | PSM | OBSERVANT, 2010–2012, Italy | 1 year | 650/650 | 81/80 | 25/25 | / | 22/22 | / | 15/13 | 9.5/10.2 (LES) | SAPIEN/CoreValve | 51/51 | 0.7/0.7 |
| Schaefer, (2019) (23) | PSM | University Heart Center Hamburg, Hamburg, Germany | 30 day | 109/109 | 76/74 | 16/22 | / | / | 30/30 | / | 2.0/2.0 (LES 2) | 44/42 | 0.8/0.8 | |
| Tzamalis et al. (2020) (24) | PSM | TAVI Karlsruhe registry | 6 year | 216/216 | 78/78 | / | / | / | 48/48 | / | 8.7/8.8 (LES) | SAPIEN/CoreValve | / | / |
| Castrodeza et al. (2016) (25) | PSM | Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 2009–2014 | 1 year | 70/70 | 79/78 | 37/26 | 64/73 | 30/16 | / | / | 4.6/4.3 | SAPIEN/CoreValve | 50/50 | 0.6/0.7 |
| Auffret, (2017) (26) | PSM | Québec Heart and Lung Institute, Québec, Canada, and Rennes University Hospital, Rennes, France, 2007–2015 | 1 year | 71/71 | 74/73 | / | / | / | 44/61 | / | 4.4/4.4 | SAPIEN/CoreValve | 44/37 | / |
| Piazza et al. (2013) (27) | PSM | SURTAVI-PSM | 1 year | 255/255 | 81/80 | 31/24 | 87/81 | 19/16 | 62/61 | / | 17.3/17.6 (LES) | / | / | / |
| Osnabrugge, (2012) (28) | PSM | TAVR or SAVR at the Erasmus MC, Rotterdam, Netherlands | 1 year | 42/42 | 79/79 | 26/19 | / | 24/19 | 48/48 | / | 12.9/12.5 (LES) | / | / | / |
| Kawashima, (2017) (29) | PSM | OCEAN-TAVI registry | 30 day | 166/166 | 86/85 | / | 81/74 | 21/21 | / | 25/28 | 7.1/6.2 | SAPIEN XT | 46/51 | 0.6/0.6 |
| Sponga, (2017) (30) | PSM | University Hospital of Udine, Italy | 30 day | 40/40 | 88/87 | 15/15 | 70/80 | 30/23 | 38/58 | / | 3.2/3.2 (EuroScore II) | SAPIEN/CoreValve | 44/46 | 0.6/0.7 |
| Repossini, (2017) (31) | PSM | 7 European cardiac centers, 2010–2014 | 30 day | 142/142 | 76/76 | 29/30 | 61/59 | / | / | / | 7.2/6.7 | / | 48/49 | 0.7/0.7 |